MIRA INFORM REPORT
|
Report No. : |
342803 |
|
Report Date : |
01.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
ARAFARMA GROUP SA |
|
|
|
|
Registered Office : |
C/ Fray Gabriel De San Antonio, 6 -10 - Pol. Ind Del Henares - Guadalajara - 19004 - Guadalajara |
|
|
|
|
Country : |
Spain |
|
|
|
|
Financials (as on) : |
2012 |
|
|
|
|
Date of Incorporation : |
28.05.2002 |
|
|
|
|
Legal Form : |
Public Company |
|
|
|
|
Line of Business : |
Manufacture of
basic pharmaceutical products |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Spain |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SPAIN - ECONOMIC OVERVIEW
Spain experienced a
prolonged recession in the wake of the global financial crisis. GDP contracted
by 3.7% in 2009, ending a 16-year growth trend, and continued contracting
through most of 2013. Economic growth resumed briefly in late 2013, albeit only
modestly, as credit contraction in the private sector, fiscal austerity, and
high unemployment continued to weigh on domestic consumption and investment.
Exports, however, have been resilient throughout the economic downturn and
helped to bring Spain's current account into surplus in 2013 for the first time
since 1986. The unemployment rate rose from a low of about 8% in 2007 to more
than 26% in 2013, straining Spain's public finances as spending on social
benefits increased while tax revenues fell. Spain’s budget deficit peaked at
11.4% of GDP in 2010. Spain gradually reduced the deficit to just under 7% of
GDP in 2013-14, slightly above the 6.5% target negotiated between Spain and the
EU. Public debt has increased substantially – from 60.1% of GDP in 2010 to more
than 97% in 2014. Rising labor productivity, moderating labor costs, and lower
inflation have helped to improve foreign investor interest in the economy and
to reduce government borrowing costs. The government's ongoing efforts to implement
reforms - labor, pension, health, tax, and education - are aimed at supporting
investor sentiment. The government also has shored up struggling banks exposed
to Spain's depressed domestic construction and real estate sectors by
successfully completing an EU-funded restructuring and recapitalization program
in January 2014. Recently increased private consumption helped bring real GDP
growth back into positive territory at 1.3% in 2014, and labor reforms prompted
a modest reduction in the unemployment rate, from more than 26% in 2013 to 24%
in 2014. Despite the uptic in economic activity, inflation dropped sharply,
from 1.5% in 2013 to flat in 2014. Spain’s 2015 budget, published in September
2014, rolls back some recently imposed taxes in advance of national elections
in November 2015 and leaves untouched the country’s value-added tax (VAT)
regime, which generates significantly lower revenue than the EU average.
Spain’s borrowing costs are dramatically lower since their peak in mid-2012.
|
Source
: CIA |
EXECUTIVE
SUMMARY
|
Name: |
ARAFARMA
GROUP SA |
|
NIF
/ Fiscal code: |
A83331827 |
|
Status: |
ACTIVE |
|
Incorporation
Date: |
28/05/2002 |
|
Register Data |
Register
Section 8 Sheet 7588 |
|
Last Publication in BORME: |
27/05/2015
[Board Meeting] |
|
Last
Published Account Deposit: |
2012 |
|
Share
Capital: |
14.409.750 |
|
|
|
|
Localization: |
C/
FRAY GABRIEL DE SAN ANTONIO, 6 -10 - POL. IND.DEL HENARES - GUADALAJARA -
19004 - GUADALAJARA |
|
Telephone
- Fax - Email - Website: |
Telephone.
949 225 622 Email. info@arafarma.com Website. www.arafarma.com |
|
|
|
|
Activity: |
|
|
NACE: |
2110
- Manufacture of basic pharmaceutical products |
|
Registered
Trademarks: |
|
|
Audited
/ Opinion: |
Si
/ |
|
Tenders
and Awards: |
|
|
Subsidies: |
2
for a total cost of 331556.06999999994 |
|
Quality
Certificate: |
No |
|
Payment
Behaviour: |
Unknown
|
|
Prospects: |
Consolidation |
|
Industry
situation: |
Maturity |
|
|
|
|
Defaults, Legal Claims and
Insolvency Proceedings : |
|
|
|
|
|
|
Number |
Amount
(€) |
Most
Recent Entry |
|
Insolvency
Proceedings, Bankruptcy and Suspension of Payments |
Unpublished |
--- |
--- |
|
Defaults
on debt with Financial Institutions and Large Companies |
None |
--- |
--- |
|
Judicial
Claims (Notices, Executive Proceedings, Attachments, Auctions, Bad Debt) |
None |
0 |
--- |
|
Proceedings
heard by the Civil Court |
Unpublished |
0 |
--- |
|
Proceedings
heard by the Labour Court |
Unpublished |
0 |
--- |
|
|
|
Partners: |
|
|
|
INDUSTRIAL
FARMACEUTICA CANTABRIA SA |
11.45
% |
|
|
Shares: |
2 |
|
|
Other
Links: |
2 |
|
|
No.
of Active Corporate Bodies: |
SINGLE
ADMINISTRATOR 1 |
|
|
Ratios |
2012 |
2011 |
Change |
|
|
|
|
|
Guarantees: |
|
|
Properties
Registered: |
Company
NO, Administrator NO |
|
Financing
/ Guarantee Sources : |
Sources
YES, Guarantees YES |
|
|
|
|
|
|
|
INVESTIGATION
SUMMARY |
|
|
This
company was incorporated in 2002. It''s engaged in production of
pharmaceutical specialties and enjoys a good concept among the sources
consulted. It meets payment commitments on a normal basis. |
|
Enquiry
Details
|
Business address regime: |
Propiedad |
Identification
|
Social Denomination: |
ARAFARMA GROUP SA |
|
NIF / Fiscal code: |
A83331827 |
|
Corporate Status: |
ACTIVE |
|
Start of activity: |
2002 |
|
Registered Office: |
C/ FRAY GABRIEL DE SAN
ANTONIO, 6 -10 - POL. IND.DEL HENARES |
|
Locality: |
GUADALAJARA |
|
Province: |
GUADALAJARA |
|
Postal Code: |
19004 |
|
Telephone: |
949 225 622 |
|
Fax: |
949 228 225 |
|
Website: |
www.arafarma.com |
|
Email: |
info@arafarma.com |
Activity
|
NACE: |
2110 |
|
Legal Form: |
PRODUCTION, BUYIND AND SELLING OF PHARMACEUTICAL AND CHEMICAL
PRODUCTS. IMPORT AND EXPORT OF RAW MATERIALS IN RELATION TO THE ACTIVITIES
INDICATED. |
|
Additional Information: |
Production and commercialisation of pharmaceutical
products. |
|
Additional Address: |
Registered office and offices C/ FRAY GABRIEL DE SAN
ANTONIO, 6 -10 - POL. IND.DEL HENARES 19004 GUADALAJARA |
|
Import / export: |
IMPORTS / EXPORTS |
|
Future Perspective: |
Consolidation |
|
Industry situation: |
Maturity |
Chronological
Summary
|
Year |
Act |
|
2002 |
Appointments/ Re-elections (1) Company Formation (1) |
|
2003 |
Accounts deposit (year 2002) Change of Social Denomination (1)
Increase of Capital (3) Statutory Modifications (2) |
|
2004 |
Accounts deposit (year 2003) |
|
2005 |
Accounts deposit (year 2004) Board Meeting (1) |
|
2006 |
Accounts deposit (year 2005) Other Concepts/ Events (1) |
|
2007 |
Appointments/ Re-elections (1) Board Meeting (1) |
|
2008 |
Accounts deposit (year 2006) Appointments/ Re-elections (1) Board Meeting
(2) Cessations/ Resignations/ Reversals (1) |
|
2009 |
Accounts deposit (year 2007) Board Meeting (1) Dividends Payment (1)
Increase of Capital (3) |
|
2010 |
Accounts deposit (year 2008) Board Meeting (1) Change of Social
address (1) |
|
2011 |
Board Meeting (1) |
|
2012 |
Board Meeting (1) |
|
2013 |
Accounts deposit (year 2009, 2010, 2011) Appointments/ Re-elections
(1) Board Meeting (2) |
|
2014 |
Board Meeting (2) |
|
2015 |
Accounts deposit (year 2012) Board Meeting (1) |
Breakdown
of Owners' Equity
|
Registered Capital: |
14.409.750 |
|
Paid up capital: |
14.409.750 |
Updated Evolution of the Subscribed and
Paid-in Capital
|
Publishing Date |
Registration Type |
Capital Subscribed |
Paid up capital |
Underwritten result |
Disbursed Result |
|
14/06/2002 |
Company Formation |
90.000 |
90.000 |
90.000 |
90.000 |
|
05/02/2003 |
Increase of Capital |
910.000 |
910.000 |
1.000.000 |
1.000.000 |
|
19/12/2003 |
Increase of Capital |
2.065.000 |
2.065.000 |
3.065.000 |
3.065.000 |
|
22/12/2003 |
Increase of Capital |
60.000 |
15.000 |
3.125.000 |
3.080.000 |
|
25/03/2009 |
Capital call payment |
--- |
45.000 |
3.125.000 |
3.125.000 |
|
25/03/2009 |
Increase of Capital |
7.537.500 |
7.537.500 |
10.662.500 |
10.662.500 |
|
27/03/2009 |
Increase of Capital |
1.557.500 |
1.557.500 |
12.220.000 |
12.220.000 |
|
27/03/2009 |
Increase of Capital |
2.189.750 |
2.189.750 |
14.409.750 |
14.409.750 |
Active
Social Bodies
|
Post published |
Social Body's Name |
Appointment Date |
Other Positions in this Company |
|
SINGLE ADMINISTRATOR |
PHARMA AFFAIRS SL |
07/05/2013 |
2 |
|
REPRESENTATIVE |
PICORNELL DARDER CARLOS |
10/04/2008 |
1 |
Historical
Social Bodies
|
Social Body's Name |
Post published |
End Date |
Other Positions in this Company |
|
GARCIA ARRANZ FRANCISCO JOSE |
SINGLE ADMINISTRATOR |
13/07/2007 |
2 |
|
|
SINGLE ADMINISTRATOR |
10/04/2008 |
|
|
PHARMA AFFAIRS SL |
SINGLE ADMINISTRATOR |
07/05/2013 |
2 |
Executive
board
|
Post |
NIF |
Name |
|
FINANCIAL DIRECTOR |
|
CARLOS PICORNELL DARDER |
Defaults,
Legal Claims and Insolvency Proceedings
Section enabling assessment of the degree of compliance of the company queried with its payment obligations. It provides information on the existence and nature of all stages of Insolvency and Legal Proceedings published with reference to the Company in the country's various Official Bulletins and national newspapers, as well Defaults Registered in the main national credit bureaus (ASNEF Industrial and RAI ).
> Summary
Chronological
summary
|
|
|
Number
of Publications |
Amount
(_) |
Start
date |
End
date |
|
Insolvency
Proceedings, Bankruptcy and Suspension of Payments |
|
Unpublished |
--- |
--- |
--- |
|
Request/Declaration |
|
0 |
--- |
date |
|
|
Proceedings |
|
--- |
--- |
|
--- |
|
Resolution |
|
--- |
--- |
|
--- |
|
Defaults
on debt with Financial Institutions and Large Companies |
Bank
and Commercial Delinquency |
None |
0 |
|
|
|
Status:
Friendly |
|
--- |
|
|
|
|
Status:
Pre-Litigation |
|
--- |
|
|
|
|
Status:
Litigation |
|
--- |
|
|
|
|
Status:
Non-performing |
|
--- |
|
|
|
|
Status:
insolvency proceedings, bankruptcy and suspension of payments |
|
--- |
|
|
|
|
Other
status |
|
--- |
|
|
|
|
Legal
and Administrative Proceedings |
|
Unpublished |
--- |
|
|
|
Notices
of defaults and enforcement |
|
--- |
--- |
|
--- |
|
Seizures |
|
--- |
--- |
|
--- |
|
Auctions |
|
--- |
--- |
|
--- |
|
Declarations
of insolvency and bad debt |
|
--- |
--- |
|
--- |
|
Proceedings
heard by the Civil Court |
|
Unpublished |
--- |
|
|
|
Proceedings
heard by the Labour Court |
|
Unpublished |
--- |
|
|
> Basis for scoring
|
Positive Factors |
Adverse Factors |
|
No judicial claims have been detected in the Official Gazettes, regarding
any Entity's outstanding debts with the Tax Bureau or Social Security
administrations, as submitted by Courts of the various court jurisdictions. No irregular payment performance has been detected based on
information obtained from credit bureaus. ARAFARMA GROUP SA has received a grant within the last twelve months.
As a prerequisite to obtaining a grant, it has had to prove its financial and
technical solvency as stated by the laws in force. Related companies without judicial claims . Neither judicial,
administrative claims nor serious actions against companies related to the
entity have been published in BORME, which indicates a tendency to meet their
obligations. It participates in other companies, a fact that allows it to diversify
not only its activity but also the risk assumed by the legal entity, as well
as enjoy the competitive advantages of such participation. |
Its annual accounts has been submitted regularly since the beginning
of its activities; however, there have been no more deposits since fiscal
year 2012. Possible difficulty accessing financing. Uncertainties about economic
recovery will hinder access to credit for new projects or for obtaining the
liquidity necessary for short-term needs. The path traveled by the entity has highlighted the lack of stability
in corporate bodies . |
Probability
of default
> Estimated Probability of Default for the next 12 months: 3.231 %
|
Sector in which comparison is carried out: 211 Manufacture of basic pharmaceutical products |
|
|
Relative Position:
|
The company's comparative analysis with the rest of the companies that comprise the sector, shows the company holds a better position with regard to the probability of non-compliance.
The 54.00% of the companies of the sector ARAFARMA GROUP SA belongs to show a higher probability of non-compliance.
The probability of the company's non-compliance with its payment obligations within deadlines estimated by our qualifications models is 3.231%.
In the event they fail to comply with the payment, the seriousness of the loss will depend on factors such as the promptness of the commencement of the charging management, the existence of executive documents which match the credit or the existence of guarantees and free debt assets under the name of the debtor. Therefore, the probability of non-compliance should not be solely interpreted as the total loss of the owed amount.
LEGAL
CLAIMS
|
Summary of Judicial Claims |
|
|
|
|
|
|
|
|
||
|
|
|
No
se han publicado |
|
|
|
|
No
se han publicado |
|
|
|
|
||
|
|
|
No
se han publicado |
|
|
|
|
No
se han publicado |
|
|
|
|
No
se han publicado |
|
|
|
|
No
se han publicado |
|
|
|
|
||
|
|
|
No
se han publicado |
|
|
|
|
No
se han publicado |
|
|
|
|
||
|
|
|
No
se han publicado |
|
Link
List
|
HAS IN ITS ADMINISTRATION BOARD TO: |
1 Entities |
|
IS RELATED WITH: |
1 Entities |
|
PARTICIPATES IN: |
2 Entities |
|
SHAREHOLDERS: |
1 Entities |
> Shareholders
|
Relationship |
Entity |
Province |
Shareholding stake |
|
SHAREHOLDERS |
INDUSTRIAL FARMACEUTICA CANTABRIA SA |
CANTABRIA |
11.45 |
|
PARTICIPATES IN |
ACYGEN SL |
MADRID |
48.9 |
|
|
PHARMA VENTILUS SL |
MADRID |
48.9 |
> Other relationships
|
Relationship |
Entity |
Province |
Shareholding stake |
|
IS RELATED WITH |
PHARMA AFFAIRS S.L |
MADRID |
|
|
HAS IN ITS ADMINISTRATION
BOARD TO |
PHARMA AFFAIRS S.L |
MADRID |
|
Turnover
|
Total Sales 2014 |
3.450.000 |
The sales data is from the latest available financial statements. Failing that, are estimates data calculated by statistical methods.
Estimated
Balance
|
FINANCIAL YEAR 2014 (X
1000 EUROS) TOTAL ASSETS..............................................20.200
NON CURRENT ASSETS.................................14.000 CURRENT
ASSETS...........................................6.200 LIABILITIES OWN
FUNDS...................................................12.200 NON CURRENT
LIABILITIES..............................4.100 CURRENT
LIABILITIES......................................3.900 |
Financial
Accounts and Balance Sheets
Financial Years Presented
|
Ejercicio |
Tipo
de Cuentas Anuales |
Fecha
Presentacion |
|
2012 |
Normales |
August
2015 |
|
2011 |
Normales |
March
2013 |
|
2010 |
Normales |
March
2013 |
|
2009 |
Normales |
March
2013 |
|
2008 |
Normales |
June
2010 |
|
2007 |
Normales |
February
2009 |
|
2006 |
Normales |
April
2008 |
|
2005 |
Normales |
November
2006 |
|
2004 |
Normales |
August
2005 |
|
2003 |
Normales |
December
2004 |
|
2002 |
Normales |
August
2003 |
The data in the
report regarding the last Company Accounts submitted by the company is taken
from the TRADE REGISTER serving the region in which the company's address is
located 31/12/2012
> Balance en formato Pyme de acuerdo al Nuevo Plan General Contable 2007
Information
corresponding to the fiscal year 2012 2011 2010 2008 is
taken from information submitted to the TRADE REGISTER. Data corresponding to
fiscal years before 2012 2011 2010 2008 has been compiled
based on the equivalence criteria stipulated in Act JUS/206/2009. Where the
provisions of the Act did not establish relevant equivalence criteria. To view
details on the methodology.
|
|
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
EQUIVALENCIA |
|
|
Assets |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
A)
NON-CURRENT ASSETS: 11000 |
13.756.856,00 |
13.068.259,00 |
13.837.928,00 |
13.884.945,00 |
12.925.302,00 |
|
|
I. Intangible fixed assets : 11100 |
3.443.519,00 |
3.069.046,00 |
3.331.634,00 |
2.275.462,00 |
1.757.095,00 |
|
|
II. Tangible fixed assets : 11200 |
9.036.970,00 |
9.225.201,00 |
9.455.912,00 |
10.606.464,00 |
11.165.247,00 |
|
|
III. Real estate investment: 11300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Long-term investments in Group companies and associates :
11400 |
2.960,00 |
2.960,00 |
2.960,00 |
2.960,00 |
2.437,00 |
|
|
V. Long-term financial investments: 11500 |
635,00 |
635,00 |
635,00 |
635,00 |
523,00 |
|
|
VI. Assets for deferred tax : 11600 |
1.272.773,00 |
770.417,00 |
1.046.787,00 |
999.424,00 |
0,00 |
|
|
VII. Non-current trade debtors : 11700 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B)
CURRENT ASSETS: 12000 |
5.712.790,00 |
6.810.862,00 |
3.947.015,00 |
3.718.855,00 |
5.381.565,00 |
|
|
I. Stocks : 12200 |
3.849.133,00 |
4.192.012,00 |
1.572.689,00 |
1.991.681,00 |
1.497.165,00 |
|
|
II. Trade debtors and others receivable accounts : 12300 |
968.455,00 |
1.919.306,00 |
1.699.496,00 |
1.327.118,00 |
2.195.201,00 |
|
|
1. Trade debtors / accounts receivable:
12380 |
374.799,00 |
1.532.669,00 |
1.451.023,00 |
714.156,00 |
1.181.294,00 |
|
|
a) Long-term
receivables from sales and services supplied : 12381 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Customers for
sales and provisions of services : 12382 |
374.799,00 |
1.532.669,00 |
1.451.023,00 |
714.156,00 |
1.181.294,00 |
|
|
2. Called up share capital: 12370 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other accounts receivable : 12390 |
593.656,00 |
386.637,00 |
248.473,00 |
612.962,00 |
1.013.907,00 |
|
|
III. Short-term investment in Group companies and associates:
12400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Short-term financial investments : 12500 |
6.061,00 |
4.062,00 |
2.069,00 |
87.142,00 |
167.142,00 |
|
|
V. Short-term accruals : 12600 |
230.021,00 |
203.482,00 |
310.903,00 |
0,00 |
0,00 |
|
|
VI. Cash and other equivalent liquid assets : 12700 |
659.120,00 |
492.000,00 |
361.859,00 |
312.914,00 |
1.522.057,00 |
|
|
TOTAL
ASSETS (A + B) : 10000 |
19.469.645,00 |
19.879.121,00 |
17.784.943,00 |
17.603.800,00 |
18.306.867,00 |
|
|
|
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
EQUIVALENCIA |
|
|
Liabilities
and Net Worth |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
A)
NET WORTH: 20000 |
11.991.787,00 |
13.547.645,00 |
12.880.372,00 |
13.022.847,00 |
13.487.076,00 |
|
|
A-1)
Shareholders' equity: 21000 |
11.991.787,00 |
13.547.645,00 |
12.880.372,00 |
13.022.847,00 |
13.487.076,00 |
|
|
I. Capital: 21100 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
|
|
1. Registered capital : 21110 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
|
|
2. (Uncalled capital): 21120 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Share premium: 21200 |
1.498.900,00 |
1.498.900,00 |
1.498.900,00 |
1.498.900,00 |
1.498.900,00 |
|
|
III. Reserves: 21300 |
-61.426,00 |
-61.426,00 |
-61.426,00 |
-61.426,00 |
-238.015,00 |
|
|
IV. (Common stock equity): 21400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Profit or loss brought forward: 21500 |
-2.299.579,00 |
-2.966.852,00 |
-2.987.536,00 |
-2.183.559,00 |
-623.738,00 |
|
|
VI. Other shareholders' contributions: 21600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VII. Result of the period: 21700 |
-1.555.857,00 |
667.273,00 |
20.684,00 |
-640.817,00 |
-1.559.821,00 |
|
|
VIII. (Interim dividend): 21800 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A-2)
Changes in net worth : 22000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A-3)
Received subsidies, donations and legacies: 23000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B)
NON-CURRENT LIABILITIES: 31000 |
3.779.221,00 |
2.469.451,00 |
2.496.788,00 |
2.963.979,00 |
3.600.916,00 |
|
|
I. Long-term provisions: 31100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Long-term creditors : 31200 |
3.779.221,00 |
2.469.451,00 |
2.496.788,00 |
2.963.979,00 |
3.600.916,00 |
|
|
1. Amounts owed to credit institutions:
31220 |
921.149,00 |
1.271.058,00 |
1.516.806,00 |
1.855.166,00 |
2.253.827,00 |
|
|
2. Creditors from financial leasing :
31230 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other long-term creditors : 31290 |
2.858.072,00 |
1.198.394,00 |
979.981,00 |
1.108.813,00 |
1.347.089,00 |
|
|
III. Long-term debts with Group companies and associates:
31300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Liabilities for deferred tax: 31400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
V. Long-term accruals: 31500 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Non-current trade creditors : 31600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VII. Special long-term debts : 31700 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
C)
CURRENT LIABILITIES : 32000 |
3.698.637,00 |
3.862.025,00 |
2.407.784,00 |
1.616.974,00 |
1.218.875,00 |
|
|
I. Short-term provisions: 32200 |
0,00 |
0,00 |
0,00 |
78.211,00 |
0,00 |
|
|
II. Short-term creditors : 32300 |
348.959,00 |
588.624,00 |
457.536,00 |
264.156,00 |
209.242,00 |
|
|
1. Amounts owed to credit institutions:
32320 |
303.874,00 |
397.499,00 |
266.411,00 |
264.071,00 |
209.175,00 |
|
|
2. Creditors from financial leasing :
32330 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
3. Other short-term creditors :
32390 |
45.085,00 |
191.125,00 |
191.125,00 |
85,00 |
67,00 |
|
|
III. Short-term amounts owed to group and associated companies:
32400 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Trade creditors and other accounts payable: 32500 |
3.349.678,00 |
3.273.401,00 |
1.950.248,00 |
1.274.607,00 |
1.009.633,00 |
|
|
1. Suppliers: 32580 |
1.969.149,00 |
2.599.889,00 |
1.029.373,00 |
767.175,00 |
607.690,00 |
|
|
a) Long-term debts :
32581 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Short-term debts :
32582 |
1.969.149,00 |
2.599.889,00 |
1.029.373,00 |
767.175,00 |
607.690,00 |
|
|
2. Other creditors: 32590 |
1.380.529,00 |
673.512,00 |
920.876,00 |
507.432,00 |
401.944,00 |
|
|
V. Short-term accruals : 32600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Special short-term debts : 32700 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
TOTAL
NET WORTH AND LIABILITIES (A + B + C) : 30000 |
19.469.645,00 |
19.879.121,00 |
17.784.943,00 |
17.603.800,00 |
18.306.867,00 |
|
|
|
ORIGINAL |
ORIGINAL |
ORIGINAL |
ORIGINAL |
EQUIVALENCIA |
|
|
Profit
and Loss |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
1. Net turnover: 40100 |
2.923.381,00 |
8.861.216,00 |
4.778.690,00 |
3.435.901,00 |
1.437.299,00 |
|
|
2. Changes in stocks of finished goods and work in progress:
40200 |
0,00 |
2.618.293,00 |
0,00 |
417.858,00 |
359.187,00 |
|
|
3. Works carried out by the company for its assets: 40300 |
609.764,00 |
467.920,00 |
763.546,00 |
505.436,00 |
703.947,00 |
|
|
4. Supplies : 40400 |
-1.323.797,00 |
-4.851.245,00 |
-1.748.219,00 |
-1.762.107,00 |
-1.514.692,00 |
|
|
5. Other operating income: 40500 |
118,00 |
31.562,00 |
20.629,00 |
0,00 |
0,00 |
|
|
6. Personnel costs: 40600 |
-1.123.426,00 |
-1.214.825,00 |
-1.166.066,00 |
-1.232.790,00 |
-1.099.589,00 |
|
|
7. Other operating costs: 40700 |
-2.101.542,00 |
-3.142.169,00 |
-1.716.260,00 |
-1.343.964,00 |
-1.132.286,00 |
|
|
8. Amortisation of fixed assets: 40800 |
-1.202.765,00 |
-1.167.736,00 |
-786.480,00 |
-825.660,00 |
-735.447,00 |
|
|
9. Allocation of subsidies of non-financial fixed assets and
other: 40900 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
10. Excess provisions : 41000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
11. Impairment and result of transfers of fixed assets:
41100 |
0,00 |
-431.932,00 |
0,00 |
0,00 |
0,00 |
|
|
12. Other results : 41300 |
226.456,00 |
-94.870,00 |
14.348,00 |
6.999,00 |
1.090,00 |
|
|
A)
OPERATING INCOME (1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10 + 11 + 12) :
49100 |
-1.991.811,00 |
1.076.213,00 |
160.187,00 |
-798.326,00 |
-1.980.491,00 |
|
|
13. Financial income : 41400 |
0,00 |
436,00 |
170,00 |
13.146,00 |
70.643,00 |
|
|
a) Allocation of financial subsidies,
donations and legacies: 41430 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Other financial income: 41490 |
0,00 |
436,00 |
170,00 |
13.146,00 |
70.643,00 |
|
|
14. Financial expenditure : 41500 |
-81.578,00 |
-124.161,00 |
-132.778,00 |
-130.050,00 |
-127.218,00 |
|
|
15. Changes in fair value of financial instruments :
41600 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
16. Exchange rate differences: 41700 |
15.177,00 |
-8.845,00 |
0,00 |
-224,00 |
4.077,00 |
|
|
17. Impairment and result for transfers of financial
instruments : 41800 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
18. Other financial income and expenditure: 42100 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
a) Incorporation of financial expenditure
to assets: 42110 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Financial income from arrangement with
creditors: 42120 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Other income and expenditure:
42130 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B)
FINANCIAL REVENUE ( 13 + 14 + 15 + 16 + 17 +18 ) : 49200 |
-66.402,00 |
-132.570,00 |
-132.608,00 |
-117.127,00 |
-52.497,00 |
|
|
C)
NET RESULT BEFORE TAXES ( A + B ) : 49300 |
-2.058.213,00 |
943.643,00 |
27.579,00 |
-915.454,00 |
-2.032.988,00 |
|
|
19. Income taxes : 41900 |
502.356,00 |
-276.370,00 |
-6.895,00 |
274.636,00 |
473.167,00 |
|
|
D)
RESULT OF THE PERIOD ( C + 19 ) : 49500 |
-1.555.857,00 |
667.273,00 |
20.684,00 |
-640.817,00 |
-1.559.821,00 |
|
> Normal Balance Sheet under the rules of the 1990 General Accounting Plan (repealed since 1st January of 2008)
Information corresponding to the fiscal year 2012 2011 2010 2008 has been compiled based on the equivalence criteria stipulated in Act JUS/206/2009. Where the provisions of the Act did not establish relevant equivalence criteria. To view details on the methodology 2012 2011 2010 2008 is taken from information submitted to the TRADE REGISTER.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
ORIGINAL |
|
|
ASSETS |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
A)
SHAREHOLDERS (PARTNERS) BY UNCALLED SUSCRIBED CAPITAL: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B)
FIXED ASSETS: |
12.484.083,00 |
12.297.842,00 |
12.791.141,00 |
12.885.520,00 |
13.035.918,00 |
|
|
I. Formation expenses: |
0,00 |
0,00 |
0,00 |
0,00 |
110.616,00 |
|
|
II. Intangible fixed assets: |
3.443.519,00 |
3.069.046,00 |
3.331.634,00 |
2.275.462,00 |
1.757.095,00 |
|
|
III. Tangible fixed assets: |
9.036.970,00 |
9.225.201,00 |
9.455.912,00 |
10.606.464,00 |
11.165.247,00 |
|
|
IV. Financial investments: |
3.595,00 |
3.595,00 |
3.595,00 |
3.595,00 |
2.960,00 |
|
|
V. Own shares: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Long-term trade receivables: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
C)
Deferred expenses: |
0,00 |
0,00 |
0,00 |
0,00 |
127.399,00 |
|
|
D)
CURRENT ASSETS: |
6.985.562,00 |
7.581.279,00 |
4.993.803,00 |
4.718.279,00 |
5.381.565,00 |
|
|
I. Called-up share capital (not paid): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
II. Stocks: |
3.849.133,00 |
4.192.012,00 |
1.572.689,00 |
1.991.681,00 |
1.497.165,00 |
|
|
III. Debtors: |
2.241.227,00 |
2.689.723,00 |
2.746.283,00 |
2.326.542,00 |
2.195.201,00 |
|
|
IV. Short-term investments: |
6.061,00 |
4.062,00 |
2.069,00 |
87.142,00 |
167.142,00 |
|
|
V. Short-term treasury shares: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VI. Cash at bank and in hand: |
659.120,00 |
492.000,00 |
361.859,00 |
312.914,00 |
1.522.057,00 |
|
|
VII. Prepayments and accrued income: |
230.021,00 |
203.482,00 |
310.903,00 |
0,00 |
0,00 |
|
|
GENERAL
TOTAL (A + B + C + D): |
19.469.645,00 |
19.879.121,00 |
17.784.943,00 |
17.603.800,00 |
18.544.882,00 |
|
MERCANTILE REGISTRY.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
ORIGINAL |
|
|
LIABILITIES |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
A)
EQUITY: |
11.991.787,00 |
13.547.645,00 |
12.880.372,00 |
13.022.847,00 |
13.725.091,00 |
|
|
I. Subscribed capital: |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
14.409.750,00 |
|
|
II. Share premium: |
1.498.900,00 |
1.498.900,00 |
1.498.900,00 |
1.498.900,00 |
1.498.900,00 |
|
|
III. Revaluation reserves: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
IV. Reserves: |
-61.426,00 |
-61.426,00 |
-61.426,00 |
-61.426,00 |
0,00 |
|
|
a) Differences for capital adjustment to
euros: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
b) Remaining Reserves: |
-61.426,00 |
-61.426,00 |
-61.426,00 |
-61.426,00 |
0,00 |
|
|
V. Profit or loss brought forward: |
-2.299.579,00 |
-2.966.852,00 |
-2.987.536,00 |
-2.183.559,00 |
-623.738,00 |
|
|
VI. Profit or loss for the financial year: |
-1.555.857,00 |
667.273,00 |
20.684,00 |
-640.817,00 |
-1.559.821,00 |
|
|
VII. Interim dividend paid: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
VIII. Own shares for capital reduction: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B)
Deferred income: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
C)
PROVISIONS FOR LIABILITIES AND CHARGES: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
D)
LONG TERM LIABILITIES: |
3.779.221,00 |
2.469.451,00 |
2.496.788,00 |
2.963.979,00 |
3.600.916,00 |
|
|
E)
SHORT TERM CREDITORS: |
3.698.637,00 |
3.862.025,00 |
2.407.784,00 |
1.538.763,00 |
1.218.875,00 |
|
|
F)
SHORT-TERM PROVISIONS FOR LIABILITIES AND CHARGES: |
0,00 |
0,00 |
0,00 |
78.211,00 |
0,00 |
|
|
GENERAL
TOTAL (A + B + C + D + E + F): |
19.469.645,00 |
19.879.121,00 |
17.784.943,00 |
17.603.800,00 |
18.544.882,00 |
|
MERCANTILE REGISTRY.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
ORIGINAL |
|
|
DEBIT |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
A)
CHARGES (A.1 to A.15): |
5.330.753,00 |
8.693.861,00 |
5.556.698,00 |
4.602.300,00 |
3.777.086,00 |
|
|
A.1. Operating consumption: |
1.323.797,00 |
2.232.953,00 |
1.748.219,00 |
1.344.248,00 |
1.155.505,00 |
|
|
A.2. Staff Costs: |
1.123.426,00 |
1.214.825,00 |
1.166.066,00 |
1.232.790,00 |
1.099.589,00 |
|
|
a) Wages, salaries et
al.: |
0,00 |
0,00 |
0,00 |
953.144,00 |
850.159,00 |
|
|
b) Social security
costs: |
1.123.426,00 |
1.214.825,00 |
1.166.066,00 |
279.645,00 |
249.430,00 |
|
|
A.3. Depreciation expense: |
1.202.765,00 |
1.167.736,00 |
786.480,00 |
825.660,00 |
735.447,00 |
|
|
A.4. Variation of trade provisions and
losses of unrecovered receivables: |
0,00 |
0,00 |
0,00 |
0,00 |
39.106,00 |
|
|
A.5. Other operating charges: |
2.101.542,00 |
3.142.169,00 |
1.716.260,00 |
1.343.964,00 |
1.093.180,00 |
|
|
A.I. OPERATING BENEFITS (B.1-A.1-A.2-A.3-A.4-A.5): |
0,00 |
1.603.016,00 |
145.839,00 |
0,00 |
0,00 |
|
|
A.6. Financial and similar charges: |
81.578,00 |
124.161,00 |
132.778,00 |
130.050,00 |
127.218,00 |
|
|
a) Due to liabilities
with companies of the group: |
0,00 |
0,00 |
0,00 |
114.376,00 |
111.885,00 |
|
|
b) Due to liabilities
with associated companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Due to other
debts: |
81.578,00 |
124.161,00 |
132.778,00 |
15.675,00 |
15.333,00 |
|
|
d) Losses from
financial investments: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.7. Financial investment provision
change: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.8. Exchange losses: |
0,00 |
8.845,00 |
0,00 |
224,00 |
208,00 |
|
|
A.II. POSITIVE FINANCIAL RESULTS (B.2+B.3-A.6-A.7-A.8): |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.III. PROFIT FROM ORDINARY ACTIVITIES (A.I+A.II-B.I-B.II):
|
0,00 |
1.470.446,00 |
13.231,00 |
0,00 |
0,00 |
|
|
A.9. Changes in provisions for intangible,
tangible and securities portfolio: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.10. Losses from tangible and intangible
fixed assets and portfolio: |
0,00 |
431.932,00 |
0,00 |
0,00 |
0,00 |
|
|
A.11. Losses from transactions with own shares
and debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.12. Extraordinary expenses: |
0,00 |
94.870,00 |
0,00 |
0,00 |
0,00 |
|
|
A.13. Prior year expenses and losses:
|
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.IV. EXTRAORDINARY PROFIT
(B.4+B.5+B.6+B.7+B.8-A.9-A.10-A.11-A.12-A.13): |
226.456,00 |
0,00 |
14.348,00 |
6.999,00 |
1.090,00 |
|
|
A.V. PROFIT BEFORE TAXES (A.III+A.IV-B.III-B.IV): |
0,00 |
943.643,00 |
27.579,00 |
0,00 |
0,00 |
|
|
A.14. Corporation Tax: |
-502.356,00 |
276.370,00 |
6.895,00 |
-274.636,00 |
-473.167,00 |
|
|
A.15. Miscellaneous taxes: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
A.VI. FINANCIAL YEAR RESULT (PROFIT) (A.V-A.14-A.15): |
0,00 |
667.273,00 |
20.684,00 |
0,00 |
0,00 |
|
MERCANTILE REGISTRY.
|
|
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
EQUIVALENCIA |
ORIGINAL |
|
|
CREDIT |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
B)
INCOME ( B.1 to B.8): |
3.774.896,00 |
9.361.134,00 |
5.577.382,00 |
3.961.483,00 |
2.217.265,00 |
|
|
B.1. Operating income: |
3.533.263,00 |
9.360.697,00 |
5.562.864,00 |
3.941.337,00 |
2.141.245,00 |
|
|
a) Net total sales:
|
2.923.381,00 |
8.861.216,00 |
4.778.690,00 |
3.435.901,00 |
1.437.299,00 |
|
|
b) Miscellaneous
operating income: |
609.882,00 |
499.482,00 |
784.174,00 |
505.436,00 |
703.947,00 |
|
|
B.I. PÉRDIDAS DE EXPLOTACIÓN (A.1+A.2+A.3+A.4+A.5-B.1 ): |
2.218.267,00 |
0,00 |
0,00 |
805.325,00 |
1.981.581,00 |
|
|
B.2. Financial income: |
0,00 |
436,00 |
170,00 |
13.147,00 |
70.643,00 |
|
|
a) Companies of the
group: |
0,00 |
436,00 |
170,00 |
13.146,00 |
70.643,00 |
|
|
b) In associated
companies: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Miscellaneous:
|
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
d) Profit on
financial investment: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.3. Exchange gains: |
15.177,00 |
0,00 |
0,00 |
0,00 |
4.286,00 |
|
|
B.II. NEGATIVE FINANCIAL RESULTS (A.6+A.7+A.8-B.2-B.3): |
66.402,00 |
132.570,00 |
132.608,00 |
117.127,00 |
52.497,00 |
|
|
B.III. LOSSES ON ORDINARY ACTIVITIES ( B.I + B.II - A.I - A.II
): |
2.284.668,00 |
0,00 |
0,00 |
922.453,00 |
2.034.078,00 |
|
|
B.4. Profit on disposal of both tangible
and intangible fixed assets and securities portfolio: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.5. Profit on transactions with own
shares and debentures: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.6. Capital grants transferred to profit
and loss: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.7. Extraordinary income: |
226.456,00 |
0,00 |
14.348,00 |
6.999,00 |
1.090,00 |
|
|
B.8. Income and profit of former financial
years: |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
B.IV. NEGATIVE EXTRAORDINARY RESULTS
(A.9+A.10+A.11+A.12+A.13-B.4-B.5-B.6-B.7-B.8): |
0,00 |
526.802,00 |
0,00 |
0,00 |
0,00 |
|
|
B.V. LOSSES BEFORE TAXES (B.III+B.IV-A.III-A.IV): |
2.058.213,00 |
0,00 |
0,00 |
915.454,00 |
2.032.988,00 |
|
|
B.VI. FINANCIAL YEAR RESULTS (LOSSES) (B.V+A.14+A.15): |
1.555.857,00 |
0,00 |
0,00 |
640.817,00 |
1.559.821,00 |
|
MERCANTILE REGISTRY.
CASHFLOW
STATEMENT
Model: Normal
> Source of information: Data contained in this section is taken from the information declared in the Annual Accounts submitted to the Trade Register.
|
|
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
1.
Fiscal year result before taxes.: 61100 |
-2.058.213,00 |
943.643,00 |
27.579,00 |
-915.454,00 |
-2.032.988,00 |
|
|
2.
Results adjustments.: 61200 |
1.284.343,00 |
1.291.460,00 |
919.088,00 |
1.020.775,00 |
787.736,00 |
|
|
a) Fixed Assets Amortization (+).: 61201 |
1.202.765,00 |
1.167.736,00 |
786.480,00 |
825.660,00 |
735.447,00 |
|
|
c) Variation in Provision (+/-). : 61203 |
0,00 |
0,00 |
0,00 |
78.211,00 |
0,00 |
|
|
g) Financial income (-).: 61207 |
0,00 |
-436,00 |
-170,00 |
-13.146,00 |
-74.929,00 |
|
|
h) Financial Expenses (+). : 61208 |
81.578,00 |
124.161,00 |
132.778,00 |
130.050,00 |
127.218,00 |
|
|
3.
Changes in current capital equity.: 61300 |
1.843.825,00 |
-1.686.923,00 |
-1.641.803,00 |
993.177,00 |
-680.443,00 |
|
|
a) Stock (+/-).: 61301 |
342.878,00 |
-2.619.323,00 |
-1.572.689,00 |
-494.515,00 |
-710.462,00 |
|
|
d) Debtors and other accounts receivable (+/-). : 61302 |
950.851,00 |
-219.810,00 |
-1.699.496,00 |
868.083,00 |
-168.308,00 |
|
|
c) Other current assets (+/-). : 61303 |
-28.537,00 |
105.428,00 |
-312.972,00 |
80.000,00 |
-143.035,00 |
|
|
d) Creditors and other accounts payable (+/-). : 61304 |
578.632,00 |
1.046.783,00 |
1.943.354,00 |
539.610,00 |
341.363,00 |
|
|
4.
Other cash flows for operating activities.: 61400 |
-81.578,00 |
-123.725,00 |
-132.608,00 |
-116.904,00 |
-52.289,00 |
|
|
a) Interest payments (-). : 61401 |
-81.578,00 |
-124.161,00 |
-132.778,00 |
-130.050,00 |
-127.218,00 |
|
|
c) Interest collection (+). : 61403 |
0,00 |
436,00 |
170,00 |
13.146,00 |
74.929,00 |
|
|
5.
Operating activity cash flows (1 + 2 + 3 + 4) : 61500 |
988.378,00 |
424.456,00 |
-827.744,00 |
981.595,00 |
-1.977.984,00 |
|
|
6.
Payments for investment (-).: 62100 |
-876.828,00 |
0,00 |
-13.837.928,00 |
-1.518.426,00 |
-994.900,00 |
|
|
a) Companies of the group and affiliates. : 62101 |
0,00 |
0,00 |
-2.960,00 |
-523,00 |
0,00 |
|
|
b) Intangible fixed assets. : 62102 |
-374.472,00 |
0,00 |
-3.331.634,00 |
-518.367,00 |
-713.006,00 |
|
|
c) Fixed assets. : 62103 |
0,00 |
0,00 |
-9.455.912,00 |
0,00 |
-281.895,00 |
|
|
e) Other financial assets. : 62105 |
0,00 |
0,00 |
-635,00 |
-112,00 |
0,00 |
|
|
h) Other assets. : 62108 |
-502.356,00 |
0,00 |
-1.046.787,00 |
-999.424,00 |
0,00 |
|
|
7.
Divestment payment collection (+). : 62200 |
188.231,00 |
769.669,00 |
0,00 |
558.783,00 |
21.067,00 |
|
|
b) Intangible fixed assets. : 62202 |
0,00 |
262.587,00 |
0,00 |
0,00 |
0,00 |
|
|
c) Fixed assets. : 62203 |
188.231,00 |
230.711,00 |
0,00 |
558.783,00 |
0,00 |
|
|
h) Other assets. : 62208 |
0,00 |
276.370,00 |
0,00 |
0,00 |
21.067,00 |
|
|
8.
Investment activity cash flows (6 + 7) minus Amortization: 62300 |
-1.891.362,00 |
-398.067,00 |
-14.624.409,00 |
-1.785.304,00 |
-1.709.280,00 |
|
|
9.
Payment collection and payments for equity instruments. : 63100 |
0,00 |
0,00 |
12.859.687,00 |
176.589,00 |
2.690.176,00 |
|
|
a) Issuance of equity instruments (+). : 63101 |
0,00 |
0,00 |
12.859.687,00 |
176.589,00 |
4.625.471,00 |
|
|
b) Amortization of assets instruments (-). : 63102 |
0,00 |
0,00 |
0,00 |
0,00 |
-1.559.821,00 |
|
|
e) Grants, donations and bequests received (+). : 63105 |
0,00 |
0,00 |
0,00 |
0,00 |
-375.474,00 |
|
|
10.
Payment collection and payments for financial liabilities instruments.:
63200 |
1.070.105,00 |
103.752,00 |
2.954.323,00 |
-582.023,00 |
192.946,00 |
|
|
a) Issuance : 63201 |
1.659.678,00 |
349.501,00 |
2.954.323,00 |
54.914,00 |
192.946,00 |
|
|
2. Debts incurred with credit institutions (+). : 63203 |
0,00 |
131.088,00 |
1.783.217,00 |
54.897,00 |
192.946,00 |
|
|
5. Other debts (+). : 63206 |
1.659.678,00 |
218.412,00 |
1.171.106,00 |
18,00 |
0,00 |
|
|
b) Repayment and amortization of : 63207 |
-589.573,00 |
-245.749,00 |
0,00 |
-636.938,00 |
0,00 |
|
|
2. Debts incurred with credit institutions (-).: 63209 |
-443.533,00 |
-245.749,00 |
0,00 |
-398.662,00 |
0,00 |
|
|
5. Other debts (-). : 63212 |
-146.040,00 |
0,00 |
0,00 |
-238.276,00 |
0,00 |
|
|
11.
Payments from dividends and remunerations from other assets instruments. :
63300 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
12.
Cash flows for financing activities (9+10+11).: 63400 |
1.070.105,00 |
103.752,00 |
15.814.011,00 |
-405.434,00 |
2.883.121,00 |
|
|
D)
EFFECT OF EXCHANGE RATE CHANGES: 64000 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
|
|
E)
NET INCREASE/DECREASE OF CASH OR EQUIVALENT ASSETS (+/-5+/-8+/12+/-D) :
65000 |
167.121,00 |
130.141,00 |
361.859,00 |
-1.209.143,00 |
-804.143,00 |
|
|
Cash or equivalent assets as of beginning of the fiscal year.:
65100 |
492.000,00 |
361.859,00 |
0,00 |
1.522.057,00 |
2.326.200,00 |
|
|
Cash or equivalent assets as of end of the fiscal year.:
65200 |
659.120,00 |
492.000,00 |
361.859,00 |
312.914,00 |
1.522.057,00 |
|
FINANCIAL DIAGNOSIS
> Economic-Financial Comparative Analysis
Data used in the following ratios and indicators is taken from the Annual Accounts submitted by the company to the TRADE REGISTER.
> Comparison within the Sector
|
Cash Flow |
2012 |
2011 |
Variación 2012 - 2011 |
|
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
|
Cash
Flow over Sales: |
0,06 % |
0,00 % |
0,01 % |
0,01 % |
289,24 % |
-104,06 % |
|
|
EBITDA
over Sales: |
-34,74 % |
2,62 % |
31,27 % |
4,34 % |
-211,09 % |
-39,55 % |
|
|
Cash
Flow Yield: |
0,01 % |
0,00 % |
0,01 % |
0,01 % |
31,11 % |
-103,76 % |
|
|
Profitability |
2012 |
2011 |
Variación 2012 - 2011 |
|
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
|
Operating
economic profitability: |
-11,40 % |
0,95 % |
5,89 % |
1,44 % |
-293,43 % |
-34,08 % |
|
|
Total
economic profitability: |
-10,15 % |
1,35 % |
5,37 % |
1,81 % |
-289,01 % |
-25,45 % |
|
|
Financial
profitability: |
-12,97 % |
-0,34 % |
4,93 % |
0,39 % |
-363,42 % |
-187,53 % |
|
|
Margin:
|
-62,78 % |
1,06 % |
12,51 % |
1,57 % |
-601,83 % |
-32,35 % |
|
|
Mark-up:
|
-64,66 % |
-0,22 % |
11,09 % |
0,27 % |
-682,83 % |
-182,85 % |
|
|
Solvency |
2012 |
2011 |
Variación 2012 - 2011 |
|
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
|
Liquidity:
|
0,18 |
0,23 |
0,13 |
0,22 |
39,89 |
8,31 |
|
|
Acid
Test: |
0,44 |
1,07 |
0,63 |
1,02 |
-29,38 |
5,42 |
|
|
Working
Capital / Investment: |
0,10 |
0,21 |
0,15 |
0,23 |
-30,26 |
-5,33 |
|
|
Solvency:
|
1,89 |
1,79 |
1,96 |
1,76 |
-3,79 |
1,99 |
|
|
Indebtedness |
2012 |
2011 |
Variación 2012 - 2011 |
|
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
|
Indebtedness
level: |
0,62 |
1,08 |
0,47 |
1,36 |
33,43 |
-20,70 |
|
|
Borrowing
Composition: |
1,02 |
0,80 |
0,64 |
0,83 |
59,80 |
-3,33 |
|
|
Repayment
Ability: |
44,75 |
-1.451,83 |
48,65 |
60,69 |
-8,03 |
-2.492,18 |
|
|
Warranty:
|
2,60 |
1,93 |
3,14 |
1,74 |
-17,07 |
11,02 |
|
|
Generated
resources / Total creditors: |
-0,05 |
0,04 |
0,29 |
0,05 |
-116,29 |
-5,81 |
|
|
Efficiency |
2012 |
2011 |
Variación 2012 - 2011 |
|
|||
|
|
Empresa |
Sector |
Empresa |
Sector |
Empresa |
Sector |
|
|
Productivity:
|
0,10 |
1,11 |
3,28 |
1,19 |
-97,07 |
-7,34 |
|
|
Turnover
of Collection Rights : |
3,65 |
4,25 |
4,88 |
4,13 |
-25,19 |
2,81 |
|
|
Turnover
of Payment Entitlements: |
1,02 |
2,76 |
3,24 |
2,75 |
-68,46 |
0,36 |
|
|
Stock
rotation: |
1,49 |
3,66 |
1,85 |
3,39 |
-19,26 |
8,05 |
|
|
Assets
turnover: |
0,18 |
0,90 |
0,47 |
0,92 |
-61,46 |
-2,56 |
|
|
Borrowing
Cost: |
1,09 |
2,43 |
1,96 |
2,40 |
-44,37 |
1,14 |
|
>
Trend of indicators under the General Accounting Plan of 2007 (2012, 2011,
2010, 2008, 2007)
|
Cash
Flow |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
Cash
Flow over Sales: |
0,06 % |
0,01 % |
0,08 % |
-35,19 % |
-55,95 % |
|
|
EBITDA
over Sales: |
-34,74 % |
31,27 % |
19,51 % |
0,59 % |
-83,98 % |
|
|
Cash
Flow Yield: |
0,01 % |
0,01 % |
0,02 % |
-6,87 % |
-4,37 % |
|
|
Profitability |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
Operating
economic profitability: |
-11,40 % |
5,89 % |
0,82 % |
-4,60 % |
-10,86 % |
|
|
Total
economic profitability: |
-10,15 % |
5,37 % |
0,90 % |
-4,46 % |
-10,35 % |
|
|
Financial
profitability: |
-12,97 % |
4,93 % |
0,16 % |
-4,92 % |
-11,36 % |
|
|
Margin:
|
-62,78 % |
12,51 % |
2,62 % |
-20,43 % |
-92,54 % |
|
|
Mark-up:
|
-64,66 % |
11,09 % |
0,24 % |
-3,15 % |
-95,00 % |
|
|
Solvency |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
Liquidity:
|
0,18 |
0,13 |
0,15 |
0,20 |
1,25 |
|
|
Acid
Test: |
0,44 |
0,63 |
0,86 |
1,12 |
3,19 |
|
|
Working
Capital / Investment: |
0,10 |
0,15 |
0,09 |
0,18 |
0,23 |
|
|
Solvency:
|
1,89 |
1,96 |
2,07 |
3,07 |
4,42 |
|
|
Indebtedness |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
Indebtedness
level: |
0,62 |
0,47 |
0,38 |
0,35 |
0,35 |
|
|
Borrowing
Composition: |
1,02 |
0,64 |
1,04 |
1,93 |
2,95 |
|
|
Repayment
Ability: |
44,75 |
48,65 |
13,55 |
-4,06 |
7,67 |
|
|
Warranty:
|
2,60 |
3,14 |
3,63 |
3,91 |
3,80 |
|
|
Generated
resources / Total creditors: |
-0,05 |
0,29 |
0,16 |
0,04 |
-0,16 |
|
|
Efficiency |
2012 |
2011 |
2010 |
2008 |
2007 |
|
|
Productivity:
|
0,10 |
3,28 |
1,80 |
1,02 |
-0,10 |
|
|
Turnover
of Collection Rights : |
3,65 |
4,88 |
3,27 |
2,97 |
0,98 |
|
|
Turnover
of Payment Entitlements: |
1,02 |
3,24 |
1,78 |
2,76 |
1,84 |
|
|
Stock
rotation: |
1,49 |
1,85 |
3,44 |
2,38 |
2,73 |
|
|
Assets
turnover: |
0,18 |
0,47 |
0,31 |
0,23 |
0,12 |
|
|
Borrowing
Cost: |
1,09 |
1,96 |
2,71 |
2,89 |
2,64 |
|
COMPARATIVE SECTORIAL BALANCE
Sector-based Comparison under the
rules of the New General Accounting Plan.
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
|
Variación - |
|
|
|
Empresa |
Sector |
News
|
elmundo.es |
06/09/2015 |
|
Nanotecnología
que detecta el virus de papiloma en 10 minutos |
|
|
Companies
related |
|
|
UNIVERSIDAD POLITECNICA DE VALENCIA |
|
|
ALTHIA HEALTH SL |
|
|
INNOMEDYX KNOWLEDGE IN ACTION SOCIEDAD LIMITADA |
|
|
|
|
Public
Tenders and Works Won
No Public
Tenders assigned to the name of the company.
Detail
of Subsidies appearing in Balances Memories
|
Entity |
JUNTA DE CASTILLA LA MANCHA, DIRECCION GENERAL DE
PROMOCION EMPRESARIAL Y COMERCIO |
|
Subsidy Concept |
Subvención de Capital. |
|
Project |
Desarrollo Galénico de una formulación nueva de
un principio activo. |
|
Amount Granted |
200.458,80 |
|
Notes |
Importe traspasado a resultados del ejercicio. |
|
Entity |
JUNTA DE CASTILLA LA MANCHA, DIRECCIÓN GENERAL DE
PROMOCIÓN Y DESARROLLO EMPRESARIAL. |
|
Subsidy Concept |
Subvención de Capital. |
|
Project |
Obtención de una nueva forma galénica el
Aceclofenaco |
|
Amount Granted |
131.097,27 |
|
Notes |
Importe traspasados a resultados del ejercicio. |
Research
Summary
|
This company was incorporated in 2002. It''s engaged in production of
pharmaceutical specialties and enjoys a good concept among the sources
consulted. It meets payment commitments on a normal basis. |
Sources
|
Registry of Commerce's Official Gazette. Own and external data bases
Company References |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.74 |
|
UK Pound |
1 |
Rs.99.53 |
|
Euro |
1 |
Rs.73.80 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
VNT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.